Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Standard
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. / Kröger, Nicolaus-Martin; Perez-Simon, Jose A; Myint, Han; Klingemann, Hans; Shimoni, Avichai; Nagler, Arnon; Martino, Rodrigo; Alegre, Adrian; Tomas, Jose F; Schwerdtfeger, Rainer; Kiehl, Michael; Fauser, Axel; Sayer, Herbert Gottfried; Leon, Angel; Beyer, Jörg; Zabelina, Tatjana; Ayuketang Ayuk, Francis; Miguel, San; Jesus, F; Brand, Ronald; Zander, Axel.
In: BIOL BLOOD MARROW TR, Vol. 10, No. 10, 10, 2004, p. 698-708.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
AU - Kröger, Nicolaus-Martin
AU - Perez-Simon, Jose A
AU - Myint, Han
AU - Klingemann, Hans
AU - Shimoni, Avichai
AU - Nagler, Arnon
AU - Martino, Rodrigo
AU - Alegre, Adrian
AU - Tomas, Jose F
AU - Schwerdtfeger, Rainer
AU - Kiehl, Michael
AU - Fauser, Axel
AU - Sayer, Herbert Gottfried
AU - Leon, Angel
AU - Beyer, Jörg
AU - Zabelina, Tatjana
AU - Ayuketang Ayuk, Francis
AU - Miguel, San
AU - Jesus, F
AU - Brand, Ronald
AU - Zander, Axel
PY - 2004
Y1 - 2004
N2 - We evaluated prognostic factors of melphalan/fludarabine-based dose-reduced allografts in patients with multiple myeloma. From 1998 to 2002, 120 patients with multiple myeloma were treated with melphalan/fludarabine followed by allogeneic stem cell transplantation. The cumulative risk at 1 year for treatment-related mortality (TRM) was 18% (95% confidence interval [CI], 12%-28%). In a multivariate analysis, relapse after prior high-dose chemotherapy was the most significant risk factor for TRM (hazard ratio [HR], 2.80; 95% CI, 1.16-6.74; P =.02), relapse (HR, 4.14; 95% CI, 2.04-8.38; P
AB - We evaluated prognostic factors of melphalan/fludarabine-based dose-reduced allografts in patients with multiple myeloma. From 1998 to 2002, 120 patients with multiple myeloma were treated with melphalan/fludarabine followed by allogeneic stem cell transplantation. The cumulative risk at 1 year for treatment-related mortality (TRM) was 18% (95% confidence interval [CI], 12%-28%). In a multivariate analysis, relapse after prior high-dose chemotherapy was the most significant risk factor for TRM (hazard ratio [HR], 2.80; 95% CI, 1.16-6.74; P =.02), relapse (HR, 4.14; 95% CI, 2.04-8.38; P
M3 - SCORING: Zeitschriftenaufsatz
VL - 10
SP - 698
EP - 708
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 10
M1 - 10
ER -